Premium
PDF
PDF
Download Download
EXAMS
NSG 318 INTRODUCTION TO PHARMACOLOGY EXAM 3 WITH
COMPLETE 550 REAL EXAM QUESTIONS AND CORRECT
VERIFIED ANSWERS/ GRADED A+ (MOST RECENT!!) | Questions &
Answers (Verified Answers) With Rationales ( Update)
This Document Contains:
149 Questions with Correct, Detailed and Verified Answers
2026/2027 Actual Exam Testbank
Questions & Answers (Verified Answers) With Rationales
100% Guaranteed Pass
Complete A+ Guide
Page 1
,Question 1
A patient with hypertension is being treated with a beta-blocker and a thiazide diuretic. The
patient develops hyperglycemia and hypokalemia. Which drug interaction best explains these
findings?
A) Beta-blocker-induced insulin resistance and thiazide-induced potassium wasting
B) Thiazide-induced insulin resistance and beta-blocker-induced potassium retention
C) Beta-blocker-induced glycogenolysis and thiazide-induced aldosterone release
D) Thiazide-induced hypercalcemia and beta-blocker-induced renin release
Answer: A) Beta-blocker-induced insulin resistance and thiazide-induced potassium wasting
Explanation: Beta-blockers can mask hypoglycemia and may impair insulin secretion, contributing
to hyperglycemia. Thiazide diuretics cause hypokalemia by increasing potassium
excretion. Option A correctly identifies both mechanisms. Option B reverses the effects;
thiazides do not cause insulin resistance directly, and beta-blockers do not cause
potassium retention. Options C and D describe incorrect mechanisms (beta-blockers
inhibit glycogenolysis and renin release).
Question 2
Which of the following best describes the clinical significance of the 'ceiling effect' observed with
loop diuretics?
A) Increasing the dose beyond the ceiling produces no additional diuresis but increases ototoxicity risk
B) The ceiling effect limits the maximum antihypertensive efficacy of these drugs
C) It refers to the development of tolerance after prolonged use, requiring dose escalation
D) The ceiling effect is due to saturation of plasma protein binding sites, reducing free drug
concentration
Answer: A) Increasing the dose beyond the ceiling produces no additional diuresis but increases
ototoxicity risk
Explanation: Loop diuretics exhibit a ceiling effect where doses above the ceiling produce no further
increase in diuretic response but increase the risk of adverse effects like ototoxicity.
Option A accurately describes this. Option B confuses diuretic with antihypertensive
efficacy; the ceiling applies to diuresis. Option C describes tolerance, not ceiling effect.
Option D is incorrect; ceiling effect is due to saturation of transporters in the loop of
Henle, not protein binding.
Page 2
,Question 3
A patient with a history of gout is prescribed losartan for hypertension. Which consideration is
most relevant?
A) Losartan may increase serum uric acid levels and precipitate gout flares
B) Losartan may decrease serum uric acid levels and reduce gout risk
C) Losartan has no effect on uric acid metabolism and is safe in gout
D) Losartan should be avoided in gout due to risk of hyperuricemia from renal impairment
Answer: B) Losartan may decrease serum uric acid levels and reduce gout risk
Explanation: Losartan, an angiotensin II receptor blocker, has a unique uricosuric effect that lowers
serum uric acid levels, potentially reducing gout risk. Option B is correct. Option A is
incorrect; losartan decreases uric acid. Option C is partially true but not the most
relevant; the effect is clinically significant. Option D is incorrect; losartan does not
cause hyperuricemia.
Question 4
A patient on warfarin is prescribed metronidazole for an infection. The INR increases from 2.5 to
5.0 within 48 hours. What is the most likely mechanism?
A) Metronidazole displaces warfarin from albumin binding sites
B) Metronidazole inhibits CYP2C9, reducing warfarin metabolism
C) Metronidazole reduces vitamin K absorption from the gut
D) Metronidazole increases warfarin absorption by altering gastric pH
Answer: B) Metronidazole inhibits CYP2C9, reducing warfarin metabolism
Explanation: Metronidazole is a potent inhibitor of CYP2C9, the enzyme primarily responsible for
metabolizing S-warfarin, leading to increased INR. Option B is correct. Option A is less
significant; displacement interactions are transient. Option C is not a known effect of
metronidazole. Option D is incorrect; metronidazole does not affect warfarin absorption.
Page 3
, Question 5
A patient with type 2 diabetes on metformin develops lactic acidosis. Which mechanism best
explains this adverse effect?
A) Metformin inhibits gluconeogenesis, leading to accumulation of lactate precursors
B) Metformin increases peripheral insulin sensitivity, causing excessive glucose uptake and anaerobic
metabolism
C) Metformin inhibits mitochondrial complex I, reducing hepatic lactate clearance
D) Metformin stimulates lactate production in skeletal muscle via AMPK activation
Answer: C) Metformin inhibits mitochondrial complex I, reducing hepatic lactate clearance
Explanation: Metformin inhibits mitochondrial complex I in the respiratory chain, reducing hepatic
lactate clearance and promoting lactic acidosis, especially in patients with renal
impairment. Option C is correct. Option A is incorrect; metformin inhibits
gluconeogenesis but that does not directly cause lactate accumulation. Option B is
incorrect; increased insulin sensitivity does not cause lactic acidosis. Option D is
incorrect; AMPK activation does not directly stimulate lactate production.
Question 6
A patient receiving gentamicin develops acute kidney injury. Which of the following is the most
appropriate monitoring parameter to minimize nephrotoxicity?
A) Peak serum concentration
B) Trough serum concentration
C) Area under the curve (AUC) over 24 hours
D) Free serum concentration
Answer: B) Trough serum concentration
Explanation: Nephrotoxicity from aminoglycosides like gentamicin is best correlated with elevated
trough concentrations, indicating accumulation. Monitoring trough levels helps adjust
dosing intervals to prevent toxicity. Option B is correct. Peak levels correlate with
efficacy, not toxicity. AUC monitoring is used for some drugs but not standard for
aminoglycosides. Free concentration is not routinely monitored.
Page 4
Download Download
EXAMS
NSG 318 INTRODUCTION TO PHARMACOLOGY EXAM 3 WITH
COMPLETE 550 REAL EXAM QUESTIONS AND CORRECT
VERIFIED ANSWERS/ GRADED A+ (MOST RECENT!!) | Questions &
Answers (Verified Answers) With Rationales ( Update)
This Document Contains:
149 Questions with Correct, Detailed and Verified Answers
2026/2027 Actual Exam Testbank
Questions & Answers (Verified Answers) With Rationales
100% Guaranteed Pass
Complete A+ Guide
Page 1
,Question 1
A patient with hypertension is being treated with a beta-blocker and a thiazide diuretic. The
patient develops hyperglycemia and hypokalemia. Which drug interaction best explains these
findings?
A) Beta-blocker-induced insulin resistance and thiazide-induced potassium wasting
B) Thiazide-induced insulin resistance and beta-blocker-induced potassium retention
C) Beta-blocker-induced glycogenolysis and thiazide-induced aldosterone release
D) Thiazide-induced hypercalcemia and beta-blocker-induced renin release
Answer: A) Beta-blocker-induced insulin resistance and thiazide-induced potassium wasting
Explanation: Beta-blockers can mask hypoglycemia and may impair insulin secretion, contributing
to hyperglycemia. Thiazide diuretics cause hypokalemia by increasing potassium
excretion. Option A correctly identifies both mechanisms. Option B reverses the effects;
thiazides do not cause insulin resistance directly, and beta-blockers do not cause
potassium retention. Options C and D describe incorrect mechanisms (beta-blockers
inhibit glycogenolysis and renin release).
Question 2
Which of the following best describes the clinical significance of the 'ceiling effect' observed with
loop diuretics?
A) Increasing the dose beyond the ceiling produces no additional diuresis but increases ototoxicity risk
B) The ceiling effect limits the maximum antihypertensive efficacy of these drugs
C) It refers to the development of tolerance after prolonged use, requiring dose escalation
D) The ceiling effect is due to saturation of plasma protein binding sites, reducing free drug
concentration
Answer: A) Increasing the dose beyond the ceiling produces no additional diuresis but increases
ototoxicity risk
Explanation: Loop diuretics exhibit a ceiling effect where doses above the ceiling produce no further
increase in diuretic response but increase the risk of adverse effects like ototoxicity.
Option A accurately describes this. Option B confuses diuretic with antihypertensive
efficacy; the ceiling applies to diuresis. Option C describes tolerance, not ceiling effect.
Option D is incorrect; ceiling effect is due to saturation of transporters in the loop of
Henle, not protein binding.
Page 2
,Question 3
A patient with a history of gout is prescribed losartan for hypertension. Which consideration is
most relevant?
A) Losartan may increase serum uric acid levels and precipitate gout flares
B) Losartan may decrease serum uric acid levels and reduce gout risk
C) Losartan has no effect on uric acid metabolism and is safe in gout
D) Losartan should be avoided in gout due to risk of hyperuricemia from renal impairment
Answer: B) Losartan may decrease serum uric acid levels and reduce gout risk
Explanation: Losartan, an angiotensin II receptor blocker, has a unique uricosuric effect that lowers
serum uric acid levels, potentially reducing gout risk. Option B is correct. Option A is
incorrect; losartan decreases uric acid. Option C is partially true but not the most
relevant; the effect is clinically significant. Option D is incorrect; losartan does not
cause hyperuricemia.
Question 4
A patient on warfarin is prescribed metronidazole for an infection. The INR increases from 2.5 to
5.0 within 48 hours. What is the most likely mechanism?
A) Metronidazole displaces warfarin from albumin binding sites
B) Metronidazole inhibits CYP2C9, reducing warfarin metabolism
C) Metronidazole reduces vitamin K absorption from the gut
D) Metronidazole increases warfarin absorption by altering gastric pH
Answer: B) Metronidazole inhibits CYP2C9, reducing warfarin metabolism
Explanation: Metronidazole is a potent inhibitor of CYP2C9, the enzyme primarily responsible for
metabolizing S-warfarin, leading to increased INR. Option B is correct. Option A is less
significant; displacement interactions are transient. Option C is not a known effect of
metronidazole. Option D is incorrect; metronidazole does not affect warfarin absorption.
Page 3
, Question 5
A patient with type 2 diabetes on metformin develops lactic acidosis. Which mechanism best
explains this adverse effect?
A) Metformin inhibits gluconeogenesis, leading to accumulation of lactate precursors
B) Metformin increases peripheral insulin sensitivity, causing excessive glucose uptake and anaerobic
metabolism
C) Metformin inhibits mitochondrial complex I, reducing hepatic lactate clearance
D) Metformin stimulates lactate production in skeletal muscle via AMPK activation
Answer: C) Metformin inhibits mitochondrial complex I, reducing hepatic lactate clearance
Explanation: Metformin inhibits mitochondrial complex I in the respiratory chain, reducing hepatic
lactate clearance and promoting lactic acidosis, especially in patients with renal
impairment. Option C is correct. Option A is incorrect; metformin inhibits
gluconeogenesis but that does not directly cause lactate accumulation. Option B is
incorrect; increased insulin sensitivity does not cause lactic acidosis. Option D is
incorrect; AMPK activation does not directly stimulate lactate production.
Question 6
A patient receiving gentamicin develops acute kidney injury. Which of the following is the most
appropriate monitoring parameter to minimize nephrotoxicity?
A) Peak serum concentration
B) Trough serum concentration
C) Area under the curve (AUC) over 24 hours
D) Free serum concentration
Answer: B) Trough serum concentration
Explanation: Nephrotoxicity from aminoglycosides like gentamicin is best correlated with elevated
trough concentrations, indicating accumulation. Monitoring trough levels helps adjust
dosing intervals to prevent toxicity. Option B is correct. Peak levels correlate with
efficacy, not toxicity. AUC monitoring is used for some drugs but not standard for
aminoglycosides. Free concentration is not routinely monitored.
Page 4
